Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma

Auris Nasus Larynx. 2017 Feb;44(1):98-103. doi: 10.1016/j.anl.2016.04.004. Epub 2016 Jun 1.

Abstract

Objective: The aim of this study was to investigate the clinical features and prognosis of patients with squamous cell carcinoma (SCC) associated with sinonasal inverted papilloma (IP).

Methods: The medical records of 95 patients who were diagnosed with IP or SCC associated with IP were retrospectively reviewed. Out of 95 patients, 15 were diagnosed with SCC associated with IP. The clinical characteristics, treatment modalities, and survival outcomes of the patients were analyzed.

Results: The incidence of SCC associated with IP was 15.8%. Although differential diagnosis between IP and SCC associated with IP is difficult, epistaxis may be the specific symptom in SCC associated with IP cases. The 3-year disease-specific survival rate was higher in cases with T1, 2 and 3 than in cases with T4. There was no significant difference in survival rate between maxillary sinus and other primary sites. On the other hand, there was a significant difference in survival rate between the microscopic SCC with IP cases and the other cases. In addition, the patients with <70 years old better than those with >70 years old with a 3-year disease free survival of 80% versus 0%.

Conclusions: Some T4 patients were found to have a highly aggressive disease. Therefore, complete surgical resection followed by chemo-radiation therapy is the recommended treatment for patients with T4 disease to control of the primary tumor site.

Keywords: Inverted papilloma; Sinonasal tract; Squamous cell carcinoma.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Squamous Cell / complications
  • Carcinoma, Squamous Cell / diagnostic imaging
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy*
  • Chemoradiotherapy, Adjuvant*
  • Disease-Free Survival
  • Drug Combinations
  • Epistaxis / etiology
  • Female
  • Fluorouracil / therapeutic use
  • Head and Neck Neoplasms / complications
  • Head and Neck Neoplasms / diagnostic imaging
  • Head and Neck Neoplasms / pathology
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Kaplan-Meier Estimate
  • Magnetic Resonance Imaging
  • Male
  • Maxillary Sinus Neoplasms / complications
  • Maxillary Sinus Neoplasms / diagnostic imaging
  • Maxillary Sinus Neoplasms / pathology
  • Maxillary Sinus Neoplasms / therapy*
  • Middle Aged
  • Nasal Cavity
  • Nasal Obstruction / etiology
  • Neoplasm Staging
  • Neoplasms, Multiple Primary / complications
  • Neoplasms, Multiple Primary / diagnostic imaging
  • Neoplasms, Multiple Primary / pathology
  • Neoplasms, Multiple Primary / therapy*
  • Nose Neoplasms / complications
  • Nose Neoplasms / diagnostic imaging
  • Nose Neoplasms / pathology
  • Nose Neoplasms / therapy*
  • Otorhinolaryngologic Surgical Procedures*
  • Oxonic Acid / therapeutic use
  • Papilloma, Inverted / complications
  • Papilloma, Inverted / diagnostic imaging
  • Papilloma, Inverted / pathology
  • Papilloma, Inverted / therapy*
  • Paranasal Sinus Neoplasms / complications
  • Paranasal Sinus Neoplasms / diagnostic imaging
  • Paranasal Sinus Neoplasms / pathology
  • Paranasal Sinus Neoplasms / therapy
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Squamous Cell Carcinoma of Head and Neck
  • Tegafur / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Fluorouracil